Search

Displaying results 8571 - 8580 of 10000 in total
  1. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved

    Products: STRENSİQ 40 MG/1.0 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET
  2. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time. … The clinical applications of activated charcoal occured in the early 1800's.

    Mixtures: İNTESTİNOL 59,4 MG/21,3 MG/71,1 MG KAPLI TABLET, 60 ADET, FINIGAX®Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates. … Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
  4. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million.

    Mixtures: EBICOMB 5 MG/5 MG EFERVESAN TABLET, 28 ADET, DONEPTIN 5 MG/5 MG FILM KAPLI TABLET, 28 ADETCategories: N-methyl-D-aspartate Receptor Antagonist, Cytochrome P-450 CYP2A6 Inhibitors
  5. Drug

    Propofol

    go.drugbank.com/drugs/DB00818
    ApprovedInvestigationalVet approved

    IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. … Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries

    Mixtures: Anesthesia S/I-60, Anesthesia S/I-40Categories: P-glycoprotein inducers, Cytochrome P-450 Substrates
  6. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263041] It was investigated as a potential treatment of hereditary angioedema (HAE) as bradykinin was implicated in HAE swelling; specifically, mice lacking B<sub>2</sub> receptors showed reduced … [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.

    Categories: Drugs Used in Hereditary AngioedemaProducts: Icatibant Reddy 30 mg/3 ml Injektionslösung in einer Fertigspritze, İKTU 30 MG/3 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  7. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

    Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSA, YERVOY 5 mg/ml concentrate for solution for infusion
  8. Pathway

    Acylcarnitine 6-(5-hexylfuran-2-yl)hexanoylcarnitine

    smpdb.ca/view/SMP0123513
    Metabolic

    6-(5-hexylfuran-2-yl)hexanoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, 6-(5-hexylfuran-2-yl)hexanoyl-CoA reacts with L-carnitine to form 6-(5-hexylfuran-2-yl)hexanoylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  9. Drug

    Zonisamide

    go.drugbank.com/drugs/DB00909
    ApprovedInvestigational

    In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] … Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.

    Categories: Compounds used in a research, industrial, or household setting, P-glycoprotein inhibitorsSynonyms: Benzo[d]isoxazol-3-yl-methanesulfonamide, 1,2-Benzisoxazole-3-methanesulfonamide
  10. Drug

    Venlafaxine

    go.drugbank.com/drugs/DB00285
    ApprovedInvestigational

    [A252065] Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. … Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI).

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: VENOXOR®75 MG, VENLAFAXINA SUN